Monoamine Oxidase Expression During Development and Aging

Nicotra, Antonietta; Pierucci, Federica; Parvez, H.; Senatori, Ornella

doi:10.1016/s0161-813x(03)00095-0

Cited by 163 publications

(102 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased (Meszaros et al 1998;Nicotra et al 2004) or unchanged (Pivac et al 2006a) platelet MAO-B activity was found in healthy controls during aging. Since MAO is a mitochondrial enzyme, it is possible that altered MAO-B activity in AD might be a consequence of the changes in the structure of the mitochondrial membrane occurring during aging (Nicotra et al 2004).…”

Section: Discussionmentioning

confidence: 97%

“…Since MAO is a mitochondrial enzyme, it is possible that altered MAO-B activity in AD might be a consequence of the changes in the structure of the mitochondrial membrane occurring during aging (Nicotra et al 2004). As no significant correlation between age and platelet MAO-B activity was found in our patients with AD or control subjects, and our patients with AD had lower and not higher platelet MAO-B activity, age of the patients presumably did not influence reduced platelet MAO-B activity found in severely ill AD patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease

Mück‐Šeler

Presečki

Mímica

et al. 2009

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease

Mück‐Šeler

Presečki

Mímica

et al. 2009

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

“…Note that rats, mice and humans have slightly different distribution of the MAO isoenzymes (Youdim and Finberg, 1983). MAO B is low in the neonate both in mice and humans, but increases rapidly after birth (Holschneider et al, 2001, Nicotra et al, 2004.…”

Section: Expressed Protein Levelsmentioning

confidence: 98%

Molecular aspects of monoamine oxidase B

Ramsay

2016

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

Graphical abstract Highlights• MAO B activity depends on both amine and oxygen concentrations KeywordsMonoamine oxidase B; kinetics; drug design; neurotransmitter levels; platelet AbbreviationsAlzheimer's Disease, AD; Parkinson's Disease, PD; dopamine transporter, DAT; serotonin transporter, SERT; noradrenaline transporter, NET; the vesicular transporter, VMAT; Gprotein coupled receptor, GPCR; induced pluripotent stem cells, iPSC; serotonin reuptake inhibitor, SSRI; brain-derived neurotrophic factor, BDNF; multi-target designed ligands, MTDL; IC 50 , the concentration of compound required to inhibit a specified assay by 50%; K i , a kinetically measured inhibitor dissociation constant. Word count -approx 5490 (excluding references). Abstract 196 words.3

show abstract

“…67 Because the MAO-B isoform appears to be predominantly responsible for dopamine metabolism in the human basal ganglia, 10,11 inhibitors of MAO-B have been used in the therapy of PD. Furthermore, MAO-B activity, as well as density, 15,16,73 has been shown to increase with age in most brain regions, including the basal ganglia. Because MAO-B is located in the glial cells, this increased activity may be attributed to an age-associated glial cell proliferation.…”

Section: Mao-b Inhibitors In the Symptomatic Treatment Of Pdmentioning

confidence: 99%

“…12,13 Furthermore, inhibitors of the MAOs may also exert a neuroprotective effect by decreasing the production of potentially hazardous by-products of dopamine metabolism in the brain. 14 Considering that MAO-B activity exhibits an age-related increase in the human brain, [15][16][17] whereas MAO-A activity remains constant, 18 inhibition of this enzyme is especially relevant in PD.…”

Section: Introductionmentioning

confidence: 99%

Dual-Target–Directed Drugs that Block Monoamine Oxidase B and Adenosine A Receptors for Parkinson's Disease

et al. 2009

View full text Add to dashboard Cite

Summary:Inadequacies of the current pharmacotherapies to treat Parkinson's disease (PD) have prompted efforts to identify novel drug targets. The adenosine A 2A receptor is one such target. Antagonists of this receptor (A 2A antagonists) are considered promising agents for the symptomatic treatment of PD. Evidence suggests that A 2A antagonists may also have neuroprotective properties that may prevent the development of the dyskinesia that often complicates levodopa treatment. Because the therapeutic benefits of A 2A antagonists are additive to that of dopamine replacement therapy, it may be possible to reduce the dose of the dopaminergic drugs and therefore the occurrence of side effects. Inhibitors of monoamine oxidase (MAO)-B also are considered useful tools for the treatment of PD. When used in combination with levodopa, inhibitors of MAO-B may enhance the elevation of dopamine levels after levodopa treatment, particularly when used in early stages of the disease when dopamine production may not be so severely compromised. Furthermore, MAO-B inhibitors may also possess neuroprotective properties in part by reducing the damaging effect of dopamine turnover in the brain. These effects of MAO-B inhibitors are especially relevant when considering that the brain shows an age-related increase in MAO-B activity. Based on these observations, dual-target-directed drugs, compounds that inhibit MAO-B and antagonize A 2A receptors, may have value in the management of PD. This review summarizes recent efforts to develop such dual-acting drugs using caffeine as the lead compound.

show abstract

Monoamine Oxidase Expression During Development and Aging

Cited by 163 publications

References 101 publications

Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease

Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease

Molecular aspects of monoamine oxidase B

Dual-Target–Directed Drugs that Block Monoamine Oxidase B and Adenosine A Receptors for Parkinson's Disease

Contact Info

Product

Resources

About